Shingrix Vaccine Reactions: Shakiness and Chills
Your nighttime shakiness and chills without fever are common, expected reactions to the Shingrix vaccine and do not require medical intervention beyond symptomatic treatment with acetaminophen or ibuprofen.
Understanding Your Symptoms
The symptoms you're experiencing are well-documented adverse reactions to Shingrix (recombinant zoster vaccine). According to the FDA label, shivering occurs in 27% of vaccine recipients aged 50 and older, making it one of the most common systemic reactions 1. These reactions typically:
- Peak within 1-3 days post-vaccination (median onset: 1 day) 2
- Resolve within 2-3 days 1
- Are self-limited and do not indicate serious complications 3
Why This Happens
Shingrix contains an adjuvant (AS01B) that deliberately stimulates a robust immune response. This is why 85% of recipients experience local or systemic reactions 4. The vaccine is significantly more reactogenic than placebo, with systemic symptoms including:
- Shivering/chills: 27% of recipients
- Fatigue: 45%
- Myalgia: 45%
- Headache: 38%
- Fever: 21% 1
Your absence of fever, respiratory symptoms, chest pain, abdominal pain, or urinary symptoms effectively rules out alternative infectious or serious causes and confirms these are vaccine-related reactions.
Recommended Management
Symptomatic treatment with acetaminophen is appropriate and safe 5. Specifically:
- Take acetaminophen 500-1000 mg every 6 hours as needed
- Ibuprofen 400-600 mg every 6-8 hours is an alternative
- Ensure adequate hydration
- Rest as needed
When to Seek Medical Attention
While your current symptoms are benign, seek immediate evaluation if you develop:
- Fever persisting >24 hours (suggests alternative infection requiring evaluation) 5
- New fever starting >24 hours post-vaccination (not vaccine-related) 5
- Severe weakness or ascending paralysis (rare Guillain-Barré syndrome risk within 42 days post-vaccination) 1
- Signs of allergic reaction (rash, difficulty breathing, facial swelling)
Important Context
Grade 3 reactions (preventing normal activity) occur in only 2-7% of recipients 1, and serious adverse events requiring hospitalization are rare (3% of all reports) 4. The post-marketing surveillance of over 3.2 million doses showed no unexpected safety signals 4, and a comprehensive analysis of 66,849 adverse event reports confirmed the safety profile matches clinical trial data 2.
Completing Your Vaccination Series
Do not skip your second dose due to these reactions. The second dose is critical for optimal protection:
- Vaccine efficacy reaches 97.2% after both doses 3
- Protection persists at >83% for 8 years 3
- Systemic reactions after dose 2 are comparable to dose 1, though headache and shivering may be slightly more common 1
The benefits of completing the series vastly outweigh the temporary discomfort of these self-limited reactions, particularly given the high burden of herpes zoster and postherpetic neuralgia in adults ≥50 years 3.